N4-(环丙基甲基)吡啶-3,4-二胺 | 1040043-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N4-(环丙基甲基)吡啶-3,4-二胺
• 英文名称: N4-(cyclopropylmethyl)pyridine-3,4-diamine
• 英文别名: 4-N-(cyclopropylmethyl)pyridine-3,4-diamine
• CAS: 1040043-50-2
• 化学式: C₉H₁₃N₃
• 分子量: 163.222
• InChiKey: YQYUTDYRFPKXTM-UHFFFAOYSA-N

物化性质

• 沸点：
  361.7±27.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,3-二甲基丁酰氯 、 N4-(环丙基甲基)吡啶-3,4-二胺 在 N-甲基吗啉 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis

  摘要：

  A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c] pyridin-5-ium templates 2a-b, and Sulfonamide derivatives 11a-n proved to be potent agonists of the CB2 receptor. Analysis of the Lipophilic Efficiency (LipE) of potent compounds provided new insight for the design of potent, metabolically stable CB2 agonists. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.062
• 作为产物：
  描述：

  N-(cyclopropylmethyl)-3-nitro-4-pyridinamine 在 palladium on carbon 、 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 60.0h， 以88%的产率得到N4-(环丙基甲基)吡啶-3,4-二胺
  参考文献：
  名称：

  Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis

  摘要：

  A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c] pyridin-5-ium templates 2a-b, and Sulfonamide derivatives 11a-n proved to be potent agonists of the CB2 receptor. Analysis of the Lipophilic Efficiency (LipE) of potent compounds provided new insight for the design of potent, metabolically stable CB2 agonists. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.062

文献信息

• [EN] PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES<br/>[FR] DÉRIVÉS DE PYRIDOPYRAZINONE COMME STIMULATEURS DE LA SÉCRÉTION D'INSULINE, LEURS PROCÉDÉS D'OBTENTION ET LEUR UTILISATION POUR LE TRAITEMENT DU DIABÈTE
  申请人：MERCK PATENT GMBH

  公开号：WO2009109341A1

  公开（公告）日：2009-09-11

  The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.

  本发明涉及式(I)的吡啶吡嗪酮衍生物，其中X、Y、Z1、W、A和R1如权利要求1所定义，作为胰岛素分泌刺激剂。该发明还涉及制备和使用这些吡啶吡嗪酮衍生物用于糖尿病和相关病理预防和/或治疗。
• PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES
  申请人：BOTTON Gérard

  公开号：US20130023537A1

  公开（公告）日：2013-01-24

  The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1 , as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.

  本发明涉及式（I）的吡啶吡唑酮衍生物，其中X，Y，Z1，W，A和R1如权利要求1所定义，作为促进胰岛素分泌的药物。本发明还涉及这些吡啶吡唑酮衍生物的制备和使用，用于预防和/或治疗糖尿病和相关病理状态。
• US8178556B2
  申请人：——

  公开号：US8178556B2

  公开（公告）日：2012-05-15
• US8642617B2
  申请人：——

  公开号：US8642617B2

  公开（公告）日：2014-02-04
• Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis
  作者：Thomas Ryckmans、Martin P. Edwards、Val A. Horne、Ana Monica Correia、Dafydd R. Owen、Lisa R. Thompson、Isabelle Tran、Michelle F. Tutt、Tim Young

  DOI：10.1016/j.bmcl.2009.05.062

  日期：2009.8

  A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c] pyridin-5-ium templates 2a-b, and Sulfonamide derivatives 11a-n proved to be potent agonists of the CB2 receptor. Analysis of the Lipophilic Efficiency (LipE) of potent compounds provided new insight for the design of potent, metabolically stable CB2 agonists. (C) 2009 Elsevier Ltd. All rights reserved.